These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 28223123

  • 1. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
    Authier S, Pugsley MK, Koerner JE, Fermini B, Redfern WS, Valentin JP, Vargas HM, Leishman DJ, Correll K, Curtis MJ.
    J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
    [Abstract] [Full Text] [Related]

  • 2. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T, Fermini B, Gintant G, Pierson JB, Sager P, Sekino Y, Strauss DG, Stockbridge N.
    J Pharmacol Toxicol Methods; 2016 Jul; 81():15-20. PubMed ID: 27282641
    [Abstract] [Full Text] [Related]

  • 3. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
    Wallis R, Benson C, Darpo B, Gintant G, Kanda Y, Prasad K, Strauss DG, Valentin JP.
    J Pharmacol Toxicol Methods; 2018 Jul; 93():15-25. PubMed ID: 29958940
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I, Holzgrefe H.
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [Abstract] [Full Text] [Related]

  • 5. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H, Pugsley MK, Fermini B, Curtis MJ, Koerner J, Accardi M, Authier S.
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [Abstract] [Full Text] [Related]

  • 6. CiPA: Ongoing testing, future qualification procedures, and pending issues.
    Cavero I, Holzgrefe H.
    J Pharmacol Toxicol Methods; 2015 Sep; 76():27-37. PubMed ID: 26159293
    [Abstract] [Full Text] [Related]

  • 7. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
    Vicente J, Hosseini M, Johannesen L, Strauss DG.
    J Electrocardiol; 2017 Sep; 50(6):808-813. PubMed ID: 28928044
    [Abstract] [Full Text] [Related]

  • 8. Recording of multiple ion current components and action potentials in human induced pluripotent stem cell-derived cardiomyocytes via automated patch-clamp.
    Mann SA, Heide J, Knott T, Airini R, Epureanu FB, Deftu AF, Deftu AT, Radu BM, Amuzescu B.
    J Pharmacol Toxicol Methods; 2019 Sep; 100():106599. PubMed ID: 31228558
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre MP, Zamora V, Smith G, Crumb WJ, Pang L, Lyn-Cook B, Ross J, Brock M, Chvatal S, Millard D, Galeotti L, Stockbridge N, Strauss DG.
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
    Cavero I, Guillon JM, Ballet V, Clements M, Gerbeau JF, Holzgrefe H.
    J Pharmacol Toxicol Methods; 2016 Jan; 81():21-36. PubMed ID: 27233533
    [Abstract] [Full Text] [Related]

  • 11. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
    Strauss DG, Gintant G, Li Z, Wu W, Blinova K, Vicente J, Turner JR, Sager PT.
    Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
    [Abstract] [Full Text] [Related]

  • 12. Update on the ECG component of the CiPA initiative.
    Vicente J.
    J Electrocardiol; 2018 Jul; 51(6S):S98-S102. PubMed ID: 30121123
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.
    Pfeiffer ER, Vega R, McDonough PM, Price JH, Whittaker R.
    J Pharmacol Toxicol Methods; 2016 Jul; 81():263-73. PubMed ID: 27095424
    [Abstract] [Full Text] [Related]

  • 18. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study.
    Delaunois A, Mathy FX, Cornet M, Gryshkova V, Korlowski C, Bonfitto F, Koch J, Schlit AF, Hebeisen S, Passini E, Rodriguez B, Valentin JP.
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01059. PubMed ID: 36748725
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.